Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24-week, randomized, double-blind, active-controlled, phase 3 trial.
Lingding XieJie HanZhifeng ChengDexue LiuJie LiuChunrong XuWenli SunQingju LiFang BianWei ZhangJinyu ChenQian ZhuTara K ThurberJ Paul LockBo ZhangPublished in: Journal of diabetes (2024)
Bexagliflozin showed nearly identical effects and a similar safety profile to dapagliflozin when used in Chinese patients on metformin.